{"gene":"PPARG","run_date":"2026-06-10T06:43:35","timeline":{"discoveries":[{"year":1998,"finding":"PPARγ was identified as the major functional receptor for the thiazolidinedione class of insulin-sensitizing drugs; ligand binding by PPARγ leads to cofactor docking in a ligand-dependent fashion, regulating transcriptional activity in adipogenesis and systemic insulin action.","method":"Nuclear receptor biochemistry, ligand binding assays, transcriptional reporter assays","journal":"Diabetes","confidence":"High","confidence_rationale":"Tier 2 / Strong — foundational finding replicated across multiple labs, multiple orthogonal methods including ligand binding and reporter assays","pmids":["9568680"],"is_preprint":false},{"year":2002,"finding":"Upon activation, PPARγ heterodimerizes with retinoid X receptor (RXR), recruits specific cofactors, and binds to PPAR-responsive DNA elements to stimulate transcription of target genes involved in glucose and lipid metabolism.","method":"Co-immunoprecipitation, reporter assays, chromatin immunoprecipitation","journal":"Annual review of nutrition","confidence":"High","confidence_rationale":"Tier 2 / Strong — heterodimer formation and DNA binding replicated across multiple independent labs and studies","pmids":["12055342"],"is_preprint":false},{"year":2005,"finding":"PPARγ activity is regulated by ERK1/2-mediated phosphorylation of a serine residue, which attenuates its transactivation function; additionally, mitogen-activated MEK1/2 interacts directly with nuclear PPARγ and exports it from the nucleus via MEK's N-terminal nuclear export signal, providing a nucleo-cytoplasmic shuttling mechanism.","method":"Co-immunoprecipitation, subcellular fractionation, phosphorylation assays, nuclear export signal mutagenesis","journal":"Cell cycle (Georgetown, Tex.)","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — direct interaction and nuclear export demonstrated in single lab with multiple methods","pmids":["17611413"],"is_preprint":false},{"year":2008,"finding":"FABP4 triggers the ubiquitination and subsequent proteasomal degradation of PPARγ, thereby downregulating PPARγ protein levels; FABP4-null preadipocytes show increased PPARγ expression and enhanced adipogenesis, and complementation of FABP4 reverses this.","method":"Ubiquitination assays, proteasome inhibitor experiments, FABP4 knockout and complementation in preadipocytes and macrophages, Western blotting","journal":"Diabetes","confidence":"High","confidence_rationale":"Tier 2 / Strong — multiple orthogonal methods (ubiquitination assay, proteasomal inhibition, genetic rescue) in single rigorous study","pmids":["24319114"],"is_preprint":false},{"year":2008,"finding":"Klotho is a direct transcriptional target of PPARγ; a noncanonical PPAR-responsive element in the 5'-flanking region of the human klotho gene was identified by ChIP and gel shift assays, and PPARγ agonists increased klotho expression in vivo in mouse kidneys.","method":"Chromatin immunoprecipitation (ChIP), electrophoretic mobility shift assay (EMSA), promoter-reporter assays, siRNA knockdown, in vivo adenovirus overexpression","journal":"Kidney international","confidence":"High","confidence_rationale":"Tier 1–2 / Moderate — ChIP, EMSA, reporter assays, and in vivo validation in single rigorous study","pmids":["18547997"],"is_preprint":false},{"year":2008,"finding":"TNF-α inhibits PPARγ activity via activation of serine kinases including IKK, ERK, JNK, and p38; IKK acts as a dominant regulator by both inhibiting PPARγ expression and activating PPARγ corepressors.","method":"Kinase activity assays, gene expression analysis, pharmacological kinase inhibition","journal":"Biochemical and biophysical research communications","confidence":"Medium","confidence_rationale":"Tier 3 / Moderate — mechanistic pathway placement from multiple reviewed studies, but this is a review paper summarizing others' and author's experiments","pmids":["18655773"],"is_preprint":false},{"year":2008,"finding":"HDAC1 and HDAC3 are recruited to the PPARG2 promoter via sumoylated CEBPD (sumoylation at lysine 120 by SUMO1), forming a repressor complex that inactivates PPARG2 transcription; non-sumoylated CEBPD reverses this repression to activate PPARG2 during hepatic lipogenesis.","method":"5'-serial deletion reporter assays, ChIP, co-immunoprecipitation of CEBPD-HDAC1/HDAC3, sumoylation mutant analysis","journal":"Biochimica et biophysica acta","confidence":"High","confidence_rationale":"Tier 1–2 / Moderate — promoter mapping, ChIP, co-IP, and mutagenesis in a single rigorous study","pmids":["18619497"],"is_preprint":false},{"year":2012,"finding":"PPARγ directly binds to the promoters of hexokinase 2 (HK2) and pyruvate kinase M2 (PKM2) to activate their transcription in PTEN-null fatty liver; this activity and liver steatosis/tumorigenesis are under control of Akt2 kinase upstream.","method":"Chromatin immunoprecipitation, promoter binding assays, genetic mouse models (PTEN-null, Akt2 knockout)","journal":"Nature communications","confidence":"High","confidence_rationale":"Tier 1–2 / Moderate — direct promoter binding by ChIP and genetic epistasis in mouse models demonstrated in single rigorous study","pmids":["22334075"],"is_preprint":false},{"year":2013,"finding":"Lipin1 directly interacts with PPARγ through a VXXLL motif (residue 885) and a C-terminal region (residues 825–926), releasing co-repressors NCoR1 and SMRT from PPARγ in the absence of ligand, thereby activating PPARγ transcriptional activity and enhancing adipocyte differentiation; a novel transcriptional activation domain (TAD, residues 217–399) unique to lipin1 mediates PPARγ activation but not PPARα.","method":"Co-immunoprecipitation, pulldown, reporter assays, domain mutagenesis (VXXLL mutant), chromatin immunoprecipitation","journal":"The Biochemical journal","confidence":"High","confidence_rationale":"Tier 1–2 / Moderate — reciprocal Co-IP, mutagenesis of binding motif, and reporter assays in single rigorous study","pmids":["23627357"],"is_preprint":false},{"year":2014,"finding":"Thrap3 (thyroid hormone receptor-associated protein 3) directly interacts with PPARγ when it is phosphorylated at Ser273 by CDK5; this interaction controls CDK5-mediated diabetic gene programming in adipocytes, including dysregulation of adiponectin and adipsin.","method":"Co-immunoprecipitation, mass spectrometry, siRNA knockdown, antisense oligonucleotide treatment in vivo, gene expression profiling","journal":"Genes & development","confidence":"High","confidence_rationale":"Tier 2 / Moderate — co-IP, MS confirmation, in vitro knockdown, and in vivo rescue with multiple orthogonal approaches","pmids":["25316675"],"is_preprint":false},{"year":2014,"finding":"Gcn5 and PCAF acetyltransferases act upstream of PPARγ to facilitate adipogenesis by regulating RNA polymerase II elongation of PPARγ transcripts; double knockout of Gcn5/PCAF inhibits PPARγ expression and prevents adipocyte differentiation, which is rescued by ectopic PPARγ expression.","method":"Genetic knockout (double KO), ectopic PPARγ expression rescue, RNA pol II ChIP, quantitative gene expression","journal":"Molecular and cellular biology","confidence":"High","confidence_rationale":"Tier 2 / Moderate — genetic epistasis with rescue experiment and ChIP mechanistic data in single study","pmids":["25071153"],"is_preprint":false},{"year":2015,"finding":"Structural analysis of PPARγ revealed the mechanism by which the antagonist SR1664 actively antagonizes PPARγ; this enabled development of SR2595 as an inverse agonist that represses PPARγ and promotes osteogenic differentiation of bone marrow-derived mesenchymal stem cells.","method":"X-ray crystallography, structural biology, cell differentiation assays with bone marrow-derived MSCs","journal":"Nature communications","confidence":"High","confidence_rationale":"Tier 1 / Moderate — structural (crystal) data plus functional validation in primary cells in single rigorous study","pmids":["26068133"],"is_preprint":false},{"year":2015,"finding":"PPARγ protein and mRNA are present within sensory axons; after sciatic nerve injury, PPARγ protein levels increase in axons with increased retrograde transport via association with dynein, and PPARγ accumulates in the nucleus of sensory neuron cell bodies; PPARγ antagonists attenuate axonal regeneration.","method":"Immunofluorescence localization, subcellular fractionation, retrograde transport assays, co-immunoprecipitation with dynein, loss-of-function with PPARγ antagonists","journal":"Developmental neurobiology","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — direct localization, co-IP with dynein, and functional loss-of-function in same study; single lab","pmids":["26446277"],"is_preprint":false},{"year":2016,"finding":"Post-translational modifications of PPARγ at S112 and S273 differentially regulate bone biology: pS112 controls osteoblastic activity and pS273 controls osteoclastic activity; the inverse agonist SR10171 blocks pS273 but not pS112, increasing trabecular/cortical bone and normalizing metabolic parameters in vivo.","method":"In vivo mouse models (normoglycemic and hyperglycemic), phospho-specific antibodies, bone histomorphometry, pharmacological intervention","journal":"EBioMedicine","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — phospho-specific reagents, in vivo pharmacological rescue; single lab, two phenotypic endpoints","pmids":["27422345"],"is_preprint":false},{"year":2016,"finding":"PPARγ directly binds to PPAR-responsive elements (PPRE) in the FXR gene promoter in adipocytes (demonstrated by ChIP), activating FXR expression in a PPARγ agonist-dependent manner; FXR in turn binds FXRE in the SCD gene promoter to promote lipogenesis.","method":"Chromatin immunoprecipitation (ChIP), promoter reporter assays, site mutagenesis","journal":"Biochemical and biophysical research communications","confidence":"Medium","confidence_rationale":"Tier 1–2 / Moderate — ChIP and mutagenesis in single study confirming direct promoter binding","pmids":["32446390"],"is_preprint":false},{"year":2017,"finding":"CACUL1 directly binds to PPARγ through a CoRNR box 2 motif and represses PPARγ transcriptional activity and adipogenesis; CACUL1 depletion results in increased histone H3K9 acetylation and decreased H3K9 methylation at PPARγ-responsive gene promoters, through reciprocal regulation of SIRT1 and LSD1 recruitment.","method":"Co-immunoprecipitation, ChIP for histone marks, RNA-seq, siRNA knockdown, domain mutagenesis","journal":"Cell death & disease","confidence":"High","confidence_rationale":"Tier 2 / Moderate — reciprocal Co-IP with domain mapping, ChIP histone marks, RNA-seq, and functional rescue in a single multi-method study","pmids":["29233982"],"is_preprint":false},{"year":2018,"finding":"MAGED1 directly binds to PPARγ and suppresses its stability and transcriptional activity; MAGED1-deficient mice show increased PPARγ protein levels, more adipocyte precursors, and hyperplasia of white adipose tissue, along with improved insulin sensitivity.","method":"Co-immunoprecipitation, protein stability assays, MAGED1 knockout mice, gene expression analysis","journal":"The Journal of endocrinology","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — co-IP, KO mouse phenotype, and protein stability analysis; single lab","pmids":["30121577"],"is_preprint":false},{"year":2020,"finding":"Structural and conformational analysis (X-ray crystallography, NMR, HDX, MD simulations, site-directed mutagenesis) revealed that CDK5 phosphorylates PPARγ at S245 (equivalent to S273 in full-length); ligand binding can allosterically block CDK5 interaction with PPARγ from a distal site, inhibiting phosphorylation via conformational change.","method":"X-ray crystallography, NMR, HDX, protein-protein docking, MD simulations, site-directed mutagenesis","journal":"Journal of medicinal chemistry","confidence":"High","confidence_rationale":"Tier 1 / Moderate — multiple structural methods plus mutagenesis in single rigorous mechanistic study","pmids":["32239932"],"is_preprint":false},{"year":2020,"finding":"TMEM18 activates PPARG, particularly upregulating PPARG1 promoter activity; TMEM18 knockdown impairs adipocyte formation in zebrafish and human preadipocytes, placing TMEM18 upstream of PPARγ as a regulator of adipogenesis.","method":"Promoter reporter assays, siRNA knockdown, zebrafish loss-of-function, human preadipocyte differentiation assays","journal":"Cell reports","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — promoter assay plus in vivo zebrafish model and human cell validation; single lab","pmids":["33086065"],"is_preprint":false},{"year":2021,"finding":"PPARγ in osteocytes is essential for sclerostin (SOST) production; PPARγ directly binds to PPREs in the 8 kb upstream region of the Sost gene promoter, as shown by ChIP; osteocyte-specific PPARγ deletion (γOTKO) results in increased bone mass, reduced bone marrow adiposity, and protection from TZD-induced bone loss.","method":"Osteocyte-specific conditional knockout mice (Dmp1Cre), ChIP for PPARG binding at Sost promoter PPREs, site mutagenesis, gene expression correlation analysis","journal":"Bone","confidence":"High","confidence_rationale":"Tier 1–2 / Moderate — conditional KO with in vivo phenotype, ChIP with PPRE mutagenesis, and in vivo pharmacological rescue in single rigorous study","pmids":["33722775"],"is_preprint":false},{"year":2009,"finding":"PPARγ activation by rosiglitazone in macrophages represses fractalkine receptor (FR) gene transcription and prevents FR plasma membrane translocation; in endothelial cells, rosiglitazone impedes nuclear export of fractalkine (FKN), revealing a novel anti-inflammatory mechanism of PPARγ.","method":"Gene expression analysis, subcellular fractionation/immunofluorescence for receptor localization, nuclear export assays","journal":"Journal of molecular endocrinology","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — direct localization experiments plus transcriptional repression in two cell types; single lab","pmids":["19850645"],"is_preprint":false},{"year":2009,"finding":"PPARγ modulates hypothalamic TRH regulation in vivo; PPARγ agonist injection modified TRH-luc transcription in newborn mouse hypothalamus; PPARγ overexpression abrogated T3-dependent Trh repression, while RXRα overexpression rescued this effect, indicating competition for RXR as a mechanism of crosstalk between PPARγ and TRβ.","method":"In vivo intracerebral injection, reporter gene (TRH-luc) assay, shRNA knockdown, adenoviral overexpression, qPCR","journal":"Molecular and cellular endocrinology","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — in vivo reporter assay, genetic knockdown, and overexpression rescue with RXR in single study","pmids":["19900503"],"is_preprint":false},{"year":2022,"finding":"C/EBPβ (LAP* and LAP isoforms) together with CSF2 signaling selectively induces expression of Pparg isoform 2 but not isoform 1 in alveolar macrophages; C/EBPβ-deficient AMs show severe defects in proliferation, phagocytosis, and lipid metabolism causing a PAP-like syndrome.","method":"Transcriptome analysis, chromatin accessibility (ATAC-seq), conditional knockout mice, functional assays (proliferation, phagocytosis, lipid metabolism)","journal":"Science immunology","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — conditional KO with transcriptomic and functional readouts; single lab study","pmids":["36112694"],"is_preprint":false},{"year":2016,"finding":"PPARγ activation with rosiglitazone stimulates lipid synthesis in mouse meibocytes, associated with SUMO1 sumoylation of the 72 kDa PPARγ isoform and its cytoplasmic accumulation; loss of cytoplasmic PPARγ was observed in aged atrophic meibomian glands.","method":"Subcellular fractionation, immunoblotting (anti-SUMO1), CARS/Raman microspectroscopy, LipidTox staining, mRNA quantification","journal":"The ocular surface","confidence":"Medium","confidence_rationale":"Tier 3 / Moderate — sumoylation demonstrated by antibody-based methods and correlated with cytoplasmic localization and lipid synthesis; single lab","pmids":["27531629"],"is_preprint":false},{"year":2021,"finding":"Pparg activation in basal bladder urothelial progenitors induces superficial cell formation and cell cycle exit, preventing tumor formation; however, in injury-activated progenitors, Pparg activation results in luminal tumor formation that is immune-deserted, linked to downregulation of NF-κB as a Pparg target.","method":"Transgenic mouse model (VP16;Pparg activated form), in situ histology, immunofluorescence, gene expression analysis","journal":"Nature communications","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — in vivo genetic model with phenotypic and molecular readouts; single lab","pmids":["34697317"],"is_preprint":false},{"year":2010,"finding":"PPARγ activation promotes osteoclastogenesis through a transcriptional network comprising PPARγ, PGC-1β, and ERRα, which promotes both osteoclast differentiation and mitochondrial activation; PPARγ also suppresses osteoblastogenesis, creating dual opposing effects on bone homeostasis.","method":"Genetic mouse models, cell differentiation assays, gene expression analysis, reporter assays","journal":"Trends in endocrinology and metabolism: TEM","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — mechanistic review summarizing in vivo genetic findings; pathway placement supported by multiple studies cited","pmids":["20863714"],"is_preprint":false},{"year":2009,"finding":"PPARγ plays a pivotal role in controlling placental vascular proliferation; PPARγ-null embryos show unsettled balance of pro- (proliferin/PLF) and anti-angiogenic factors (proliferin-related protein/PRP), and PPARγ agonist rosiglitazone treatment disrupts placental vasculature and decreases proangiogenic gene expression.","method":"Conditional knockout mice (Sox2Cre/PPARγL2/L2), in vivo rosiglitazone treatment, gene expression analysis","journal":"Endocrinology","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — genetic KO plus pharmacological intervention with defined molecular readouts; single lab","pmids":["20810566"],"is_preprint":false},{"year":2022,"finding":"PPARγ directly regulates buffalo LPIN1 transcription by binding to two PPAR response elements (PPRE1 and PPRE2) identified in the core LPIN1 promoter region (−666 to +42 bp); site mutagenesis confirmed both PPREs are required for PPARγ-dependent LPIN1 activation and triglyceride synthesis in mammary epithelial cells.","method":"Chromatin immunoprecipitation, promoter reporter assays, site-directed mutagenesis of PPREs, overexpression/knockdown","journal":"Scientific reports","confidence":"Medium","confidence_rationale":"Tier 1–2 / Moderate — ChIP plus PPRE mutagenesis in functional assay; single lab in non-human model (buffalo)","pmids":["35149744"],"is_preprint":false},{"year":2024,"finding":"PPARG activation promotes autophagy to accelerate ROS clearance, thereby inhibiting ROS-mediated macrophage polarization and NLRP3 inflammasome activation in rheumatoid arthritis; CBD acts as a PPARγ agonist mediating this pathway.","method":"In vitro RAW264.7 cell assays, CIA rat model, autophagy flux assays, ROS measurement, NLRP3 inflammasome assays","journal":"Journal of autoimmunity","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — in vitro and in vivo models with mechanistic autophagy/ROS/NLRP3 pathway readouts; single lab","pmids":["38648706"],"is_preprint":false}],"current_model":"PPARγ (PPARG) is a ligand-activated nuclear receptor that heterodimerizes with RXR to bind PPAR-responsive elements and activate transcription of target genes governing adipogenesis, lipid/glucose metabolism, and inflammation; its activity is regulated by post-translational modifications (phosphorylation at S112 by ERK and S273 by CDK5, sumoylation, ubiquitination leading to proteasomal degradation), direct interactions with co-repressors (NCoR1, SMRT, HDAC1/3 via sumoylated CEBPD) and co-activators (lipin1, Thrap3), nucleo-cytoplasmic shuttling mediated by MEK1/2, and upstream regulation by factors including FABP4 (promoting PPARγ degradation), CACUL1 (recruiting SIRT1/LSD1), and MAGED1 (suppressing stability and activity), collectively determining cell-type-specific transcriptional programs in adipocytes, osteocytes, macrophages, neurons, and other tissues."},"narrative":{"mechanistic_narrative":"PPARγ is a ligand-activated nuclear receptor that, upon binding thiazolidinedione drugs and other ligands, drives cofactor docking and transcriptional programs governing adipogenesis, lipid and glucose metabolism, and inflammation [PMID:9568680]. Activated PPARγ heterodimerizes with RXR, recruits cofactors, and binds PPAR-responsive elements (PPREs) to stimulate metabolic target genes [PMID:12055342]; direct, ChIP-validated targets include klotho [PMID:18547997], the glycolytic enzymes HK2 and PKM2 in fatty liver [PMID:22334075], FXR in adipocytes [PMID:32446390], LPIN1 in mammary epithelium [PMID:35149744], and the osteocyte gene Sost/sclerostin [PMID:33722775]. Its output is tuned by post-translational modification and cofactor exchange: ERK1/2 phosphorylates a serine that attenuates transactivation while MEK1/2 binds nuclear PPARγ and exports it to the cytoplasm [PMID:17611413], and CDK5 phosphorylates S273/S245, a modification that recruits Thrap3 to reprogram diabetic gene expression and that ligand binding can allosterically block from a distal site [PMID:25316675, PMID:32239932]. PPARγ stability is controlled by ubiquitin-proteasome turnover triggered by FABP4 [PMID:24319114] and by direct binding of MAGED1, which suppresses receptor stability and activity [PMID:30121577]. Cofactor balance determines activation versus repression: lipin1 displaces the NCoR1/SMRT co-repressors to activate the receptor [PMID:23627357], whereas CACUL1 binds a CoRNR-box motif and represses PPARγ by reciprocally tuning SIRT1/LSD1 recruitment and histone H3K9 modifications [PMID:29233982]; PPARG2 expression itself is gated by an HDAC1/HDAC3 co-repressor complex tethered via sumoylated CEBPD [PMID:18619497]. Beyond adipocytes, PPARγ exerts cell-type-specific roles in bone, where pS112 and pS273 differentially control osteoblastic and osteoclastic activity [PMID:27422345, PMID:33722775], in macrophages and inflammation [PMID:19850645, PMID:38648706], and in sensory neurons, where it undergoes dynein-dependent retrograde axonal transport supporting regeneration [PMID:26446277]. Structural studies of inverse agonists (SR2595, SR10171) demonstrate that pharmacological repression of PPARγ promotes osteogenic differentiation and increases bone mass [PMID:26068133, PMID:27422345].","teleology":[{"year":1998,"claim":"Established PPARγ as the molecular target of insulin-sensitizing thiazolidinediones, linking a nuclear receptor to systemic glucose control via ligand-dependent transcription.","evidence":"nuclear receptor ligand-binding and transcriptional reporter assays","pmids":["9568680"],"confidence":"High","gaps":["Endogenous physiological ligands not defined","Tissue-specific target gene sets not yet mapped"]},{"year":2002,"claim":"Defined the core transcriptional mechanism: ligand-activated PPARγ heterodimerizes with RXR and binds PPREs to activate metabolic genes.","evidence":"Co-IP, reporter assays, and ChIP","pmids":["12055342"],"confidence":"High","gaps":["Genome-wide target catalog incomplete","Cofactor specificity by cell type unresolved"]},{"year":2005,"claim":"Showed that PPARγ activity is dynamically restrained by MAPK signaling through ERK-mediated serine phosphorylation and MEK1/2-driven nuclear export, a non-genomic spatial control mechanism.","evidence":"Co-IP, subcellular fractionation, phosphorylation assays, and NES mutagenesis","pmids":["17611413"],"confidence":"Medium","gaps":["Single-lab findings","Quantitative contribution of export to physiological output unknown"]},{"year":2008,"claim":"Identified multiple layers of negative regulation — FABP4-driven ubiquitination/degradation, TNF-α/IKK-mediated suppression, and sumoylated-CEBPD-tethered HDAC repressor complexes at the PPARG2 promoter — clarifying how receptor abundance and PPARG2 transcription are dampened.","evidence":"ubiquitination/proteasome assays, FABP4 knockout/complementation, kinase inhibition, promoter mapping, ChIP, and sumoylation-mutant analysis","pmids":["24319114","18655773","18619497"],"confidence":"High","gaps":["E3 ligase mediating FABP4-triggered ubiquitination not identified","Interplay among these repressive inputs not integrated"]},{"year":2008,"claim":"Extended the direct target repertoire by demonstrating PPARγ binds a noncanonical PPRE in the klotho promoter, connecting the receptor to renal klotho expression in vivo.","evidence":"ChIP, EMSA, reporter assays, and in vivo agonist treatment","pmids":["18547997"],"confidence":"High","gaps":["Physiological consequence of klotho induction not fully defined"]},{"year":2012,"claim":"Placed PPARγ within an Akt2-controlled circuit driving glycolytic gene expression (HK2, PKM2) in PTEN-null fatty liver, linking the receptor to steatosis and tumorigenesis.","evidence":"ChIP and genetic mouse epistasis (PTEN-null, Akt2 knockout)","pmids":["22334075"],"confidence":"High","gaps":["Generality beyond PTEN-null context unknown"]},{"year":2013,"claim":"Resolved a ligand-independent activation route: lipin1 binds via a VXXLL motif and a unique TAD to displace NCoR1/SMRT co-repressors, activating PPARγ and adipogenesis.","evidence":"reciprocal Co-IP, pulldown, domain mutagenesis, reporter assays, and ChIP","pmids":["23627357"],"confidence":"High","gaps":["In vivo relevance of lipin1-driven activation not quantified"]},{"year":2014,"claim":"Defined how the diabetes-associated CDK5-S273 phosphorylation is decoded — Thrap3 binds the phosphorylated receptor to reprogram adipocyte gene expression — and showed Gcn5/PCAF acetyltransferases act upstream by enabling Pol II elongation of Pparg transcripts.","evidence":"Co-IP/MS, knockdown, in vivo antisense rescue, double-knockout with ectopic-PPARγ rescue, and Pol II ChIP","pmids":["25316675","25071153"],"confidence":"High","gaps":["Full Thrap3-dependent gene program not delineated","Acetyltransferase mechanism on other loci unclear"]},{"year":2015,"claim":"Used structure-guided design to develop SR1664-derived inverse agonists (SR2595) that repress PPARγ and redirect bone-marrow MSCs toward osteogenesis, establishing antagonism as a route to alter cell fate.","evidence":"X-ray crystallography and MSC differentiation assays","pmids":["26068133"],"confidence":"High","gaps":["Long-term in vivo efficacy and selectivity not established"]},{"year":2016,"claim":"Demonstrated that distinct phosphosites partition PPARγ's skeletal effects (pS112 → osteoblastic, pS273 → osteoclastic), with SR10171 selectively blocking pS273 to increase bone and normalize metabolism, and described isoform-specific sumoylation/cytoplasmic localization in lipid-synthesizing meibocytes.","evidence":"in vivo mouse models with phospho-specific antibodies, bone histomorphometry, and subcellular fractionation with anti-SUMO1 immunoblotting","pmids":["27422345","27531629"],"confidence":"Medium","gaps":["Single-lab phenotypes","Mechanistic link between sumoylation and cytoplasmic retention not fully resolved"]},{"year":2017,"claim":"Identified CACUL1 as a CoRNR-box co-repressor that represses PPARγ by reciprocally tuning SIRT1/LSD1 recruitment and H3K9 acetylation/methylation, refining the epigenetic logic of receptor output.","evidence":"Co-IP with domain mapping, histone-mark ChIP, RNA-seq, and knockdown","pmids":["29233982"],"confidence":"High","gaps":["Physiological adipose role of CACUL1 not tested in vivo"]},{"year":2018,"claim":"Showed MAGED1 directly binds and destabilizes PPARγ, with MAGED1 loss increasing receptor levels, adipocyte precursors, and insulin sensitivity, adding a stability-control input to the network.","evidence":"Co-IP, protein stability assays, and MAGED1 knockout mice","pmids":["30121577"],"confidence":"Medium","gaps":["Single-lab study","Degradation machinery engaged by MAGED1 unspecified"]},{"year":2020,"claim":"Provided high-resolution mechanism for ligand-mediated suppression of pathogenic phosphorylation: CDK5 modifies S245/S273, and ligand binding allosterically blocks CDK5 docking from a distal site, and identified TMEM18 as an upstream activator of the PPARG1 promoter required for adipogenesis.","evidence":"X-ray/NMR/HDX/MD with mutagenesis; promoter reporter assays with zebrafish and human preadipocyte loss-of-function","pmids":["32239932","33086065"],"confidence":"High","gaps":["How TMEM18 reaches the promoter mechanistically unknown","Structural model of full-length receptor-CDK5 complex incomplete"]},{"year":2021,"claim":"Established cell-type-specific in vivo functions: osteocyte PPARγ directly drives Sost/sclerostin via promoter PPREs, and bladder urothelial PPARγ governs differentiation versus immune-deserted tumor formation depending on progenitor state.","evidence":"conditional/transgenic mouse models, ChIP with PPRE mutagenesis, and histology/expression analysis","pmids":["33722775","34697317"],"confidence":"High","gaps":["Context-dependence of tumor-promoting versus protective output not mechanistically reconciled"]},{"year":2024,"claim":"Linked PPARγ activation to anti-inflammatory autophagy: agonism accelerates ROS clearance to limit macrophage polarization and NLRP3 inflammasome activation in arthritis models.","evidence":"RAW264.7 assays, CIA rat model, autophagy flux, ROS and NLRP3 readouts","pmids":["38648706"],"confidence":"Medium","gaps":["Direct transcriptional targets mediating autophagy not identified","Single-lab study"]},{"year":null,"claim":"How the competing stability inputs (FABP4, MAGED1), cofactor exchanges (lipin1, CACUL1, Thrap3), and phosphorylation states are integrated to specify distinct tissue programs — and which endogenous ligands drive each — remains unresolved.","evidence":"","pmids":[],"confidence":"Medium","gaps":["No unified model linking PTM state to cofactor selection per cell type","Endogenous ligand identity per context undefined","E3 ligases controlling degradation not fully identified"]}],"mechanism_profile":{"molecular_activity":[{"term_id":"GO:0140110","term_label":"transcription regulator activity","supporting_discovery_ids":[0,1,4,7,14,19,27]},{"term_id":"GO:0003677","term_label":"DNA binding","supporting_discovery_ids":[1,4,7,14,19,27]},{"term_id":"GO:0008289","term_label":"lipid binding","supporting_discovery_ids":[0]}],"localization":[{"term_id":"GO:0005634","term_label":"nucleus","supporting_discovery_ids":[2,12]},{"term_id":"GO:0005829","term_label":"cytosol","supporting_discovery_ids":[2,23]}],"pathway":[{"term_id":"R-HSA-74160","term_label":"Gene expression (Transcription)","supporting_discovery_ids":[1,4,7,14,19]},{"term_id":"R-HSA-1430728","term_label":"Metabolism","supporting_discovery_ids":[0,7,27]},{"term_id":"R-HSA-1266738","term_label":"Developmental Biology","supporting_discovery_ids":[11,18,26]},{"term_id":"R-HSA-168256","term_label":"Immune System","supporting_discovery_ids":[20,22,28]}],"complexes":["PPARγ-RXR heterodimer"],"partners":["RXR","MEK1/2","FABP4","LIPIN1","THRAP3","CACUL1","MAGED1","CDK5"],"other_free_text":[]}},"prefetch_data":{"uniprot":{"accession":"P37231","full_name":"Peroxisome proliferator-activated receptor gamma","aliases":["Nuclear receptor subfamily 1 group C member 3"],"length_aa":505,"mass_kda":57.6,"function":"Ligand-activated transcription factor that forms obligate heterodimers with the retinoic acid receptor and acts as a key regulator of biological processes, such as adipocyte differentiation, lipid metabolism, glucose homeostasis and beta-oxidation of fatty acids (PubMed:16150867, PubMed:20829347, PubMed:23525231, PubMed:8702406, PubMed:8706692, PubMed:9065481). Activated by lipid ligands: binds peroxisome proliferators, such as hypolipidemic drugs, and fatty acids, such as prostaglandin J2 metabolites (PubMed:16150867, PubMed:20829347, PubMed:23525231, PubMed:8702406, PubMed:8706692, PubMed:9065481). Ligand-binding results in a conformational change in the receptor, promoting dissociation of repressors and recruitment of coactivators, and subsequent activation of target gene expression (PubMed:16150867, PubMed:20829347, PubMed:23525231, PubMed:8702406, PubMed:8706692, PubMed:9065481). Specifically binds to DNA specific PPAR response elements (PPRE) and modulates the transcription of its target genes, such as acyl-CoA oxidase (By similarity). Acts as a critical regulator of gut homeostasis by suppressing NF-kappa-B-mediated pro-inflammatory responses (PubMed:20829347). Plays a role in the regulation of cardiovascular circadian rhythms by regulating the transcription of BMAL1 in the blood vessels (By similarity) Nuclear receptor that acts as the key factor controlling the development of adipocytes (By similarity). Specifically activated by 15-deoxy-delta12,14-prostaglandin J2 ligand during early adipogenesis, driving differentiation of all types of adipocytes (white, beige and brown) (By similarity). Acts together with retinoic acid receptor RXRA, forming the ARF6 complex, which acts as a key regulator of the tissue-specific adipocyte P2 (aP2) enhancer (By similarity). Following recruitment of TLE3, promotes differentiation of white adipocytes (By similarity). Following recruitment of PRDM16, promotes differentiation of myoblastic precursors into brown adipose cells (BAT), which are specialized in dissipating energy in the form of heat in response to cold or excess feeding (By similarity). Also mediates diffentiation of white adipocytes into beige adipocytes by mediating recruitment of PRDM16 (By similarity) (Microbial infection) Upon treatment with M.tuberculosis or its lipoprotein LpqH, phosphorylation of MAPK p38 and IL-6 production are modulated, probably via this protein","subcellular_location":"Nucleus","url":"https://www.uniprot.org/uniprotkb/P37231/entry"},"depmap":{"release":"DepMap","has_data":true,"is_common_essential":false,"resolved_as":"","url":"https://depmap.org/portal/gene/PPARG","classification":"Not Classified","n_dependent_lines":33,"n_total_lines":1208,"dependency_fraction":0.027317880794701987},"opencell":{"profiled":false,"resolved_as":"","ensg_id":"","cell_line_id":"","localizations":[],"interactors":[],"url":"https://opencell.sf.czbiohub.org/search/PPARG","total_profiled":1310},"omim":[{"mim_id":"621163","title":"ADIPOGENESIS REGULATORY FACTOR; ADIRF","url":"https://www.omim.org/entry/621163"},{"mim_id":"620997","title":"SEMAPHORIN 3G; SEMA3G","url":"https://www.omim.org/entry/620997"},{"mim_id":"620847","title":"BONE MORPHOGENETIC PROTEIN 8A; BMP8A","url":"https://www.omim.org/entry/620847"},{"mim_id":"620683","title":"LIPODYSTROPHY, FAMILIAL PARTIAL, TYPE 9; FPLD9","url":"https://www.omim.org/entry/620683"},{"mim_id":"620604","title":"PROSTAGLANDIN REDUCTASE 3; PTGR3","url":"https://www.omim.org/entry/620604"}],"hpa":{"profiled":true,"resolved_as":"","reliability":"Enhanced","locations":[{"location":"Nucleoplasm","reliability":"Enhanced"},{"location":"Vesicles","reliability":"Enhanced"}],"tissue_specificity":"Tissue enhanced","tissue_distribution":"Detected in many","driving_tissues":[{"tissue":"adipose tissue","ntpm":153.2},{"tissue":"breast","ntpm":83.9}],"url":"https://www.proteinatlas.org/search/PPARG"},"hgnc":{"alias_symbol":["PPARG1","PPARG2","NR1C3","PPARgamma"],"prev_symbol":[]},"alphafold":{"accession":"P37231","domains":[{"cath_id":"3.30.50.10","chopping":"149-228","consensus_level":"high","plddt":90.6764,"start":149,"end":228},{"cath_id":"1.10.565.10","chopping":"235-502","consensus_level":"high","plddt":92.5393,"start":235,"end":502}],"viewer_url":"https://alphafold.ebi.ac.uk/entry/P37231","model_url":"https://alphafold.ebi.ac.uk/files/AF-P37231-F1-model_v6.cif","pae_url":"https://alphafold.ebi.ac.uk/files/AF-P37231-F1-predicted_aligned_error_v6.png","plddt_mean":76.12},"mouse_models":{"mgi_url":"https://www.informatics.jax.org/marker/summary?nomen=PPARG","jax_strain_url":"https://www.jax.org/strain/search?query=PPARG"},"sequence":{"accession":"P37231","fasta_url":"https://rest.uniprot.org/uniprotkb/P37231.fasta","uniprot_url":"https://www.uniprot.org/uniprotkb/P37231/entry","alphafold_viewer_url":"https://alphafold.ebi.ac.uk/entry/P37231"}},"corpus_meta":[{"pmid":"18518822","id":"PMC_18518822","title":"Fat and beyond: the diverse biology of PPARgamma.","date":"2008","source":"Annual review of biochemistry","url":"https://pubmed.ncbi.nlm.nih.gov/18518822","citation_count":1710,"is_preprint":false},{"pmid":"9568680","id":"PMC_9568680","title":"PPAR-gamma: adipogenic regulator and thiazolidinedione receptor.","date":"1998","source":"Diabetes","url":"https://pubmed.ncbi.nlm.nih.gov/9568680","citation_count":1484,"is_preprint":false},{"pmid":"16360030","id":"PMC_16360030","title":"The many faces of PPARgamma.","date":"2005","source":"Cell","url":"https://pubmed.ncbi.nlm.nih.gov/16360030","citation_count":1215,"is_preprint":false},{"pmid":"10447513","id":"PMC_10447513","title":"PPARgamma, the ultimate thrifty gene.","date":"1999","source":"Diabetologia","url":"https://pubmed.ncbi.nlm.nih.gov/10447513","citation_count":513,"is_preprint":false},{"pmid":"25083916","id":"PMC_25083916","title":"Natural product agonists of peroxisome proliferator-activated receptor gamma (PPARγ): a review.","date":"2014","source":"Biochemical pharmacology","url":"https://pubmed.ncbi.nlm.nih.gov/25083916","citation_count":444,"is_preprint":false},{"pmid":"19581903","id":"PMC_19581903","title":"Wnt and PPARgamma signaling in osteoblastogenesis and adipogenesis.","date":"2009","source":"Nature reviews. Rheumatology","url":"https://pubmed.ncbi.nlm.nih.gov/19581903","citation_count":423,"is_preprint":false},{"pmid":"12055342","id":"PMC_12055342","title":"PPAR(gamma) and glucose homeostasis.","date":"2002","source":"Annual review of nutrition","url":"https://pubmed.ncbi.nlm.nih.gov/12055342","citation_count":361,"is_preprint":false},{"pmid":"15711576","id":"PMC_15711576","title":"Regulation of PPARgamma activity during adipogenesis.","date":"2005","source":"International journal of obesity (2005)","url":"https://pubmed.ncbi.nlm.nih.gov/15711576","citation_count":347,"is_preprint":false},{"pmid":"24319114","id":"PMC_24319114","title":"FABP4 attenuates PPARγ and adipogenesis and is inversely correlated with PPARγ in adipose tissues.","date":"2013","source":"Diabetes","url":"https://pubmed.ncbi.nlm.nih.gov/24319114","citation_count":272,"is_preprint":false},{"pmid":"11900961","id":"PMC_11900961","title":"Peroxisome proliferator-activated receptor gamma (PPARgamma) and its ligands: a review.","date":"2002","source":"Domestic animal endocrinology","url":"https://pubmed.ncbi.nlm.nih.gov/11900961","citation_count":193,"is_preprint":false},{"pmid":"27268145","id":"PMC_27268145","title":"PPARγ signaling and emerging opportunities for improved therapeutics.","date":"2016","source":"Pharmacological research","url":"https://pubmed.ncbi.nlm.nih.gov/27268145","citation_count":186,"is_preprint":false},{"pmid":"24904744","id":"PMC_24904744","title":"Transcriptional and epigenetic regulation of PPARγ expression during adipogenesis.","date":"2014","source":"Cell & bioscience","url":"https://pubmed.ncbi.nlm.nih.gov/24904744","citation_count":184,"is_preprint":false},{"pmid":"29032144","id":"PMC_29032144","title":"Peroxisome proliferator-activated receptor γ (PPARγ): A master gatekeeper in CNS injury and repair.","date":"2017","source":"Progress in neurobiology","url":"https://pubmed.ncbi.nlm.nih.gov/29032144","citation_count":182,"is_preprint":false},{"pmid":"17475546","id":"PMC_17475546","title":"PPARgamma in human and mouse physiology.","date":"2007","source":"Biochimica et biophysica acta","url":"https://pubmed.ncbi.nlm.nih.gov/17475546","citation_count":175,"is_preprint":false},{"pmid":"20179158","id":"PMC_20179158","title":"The association between the peroxisome proliferator-activated receptor-gamma2 (PPARG2) Pro12Ala gene variant and type 2 diabetes mellitus: a HuGE review and meta-analysis.","date":"2010","source":"American journal of epidemiology","url":"https://pubmed.ncbi.nlm.nih.gov/20179158","citation_count":158,"is_preprint":false},{"pmid":"18655773","id":"PMC_18655773","title":"Regulation of PPARgamma function by TNF-alpha.","date":"2008","source":"Biochemical and biophysical research communications","url":"https://pubmed.ncbi.nlm.nih.gov/18655773","citation_count":149,"is_preprint":false},{"pmid":"18547997","id":"PMC_18547997","title":"Klotho is a target gene of PPAR-gamma.","date":"2008","source":"Kidney international","url":"https://pubmed.ncbi.nlm.nih.gov/18547997","citation_count":147,"is_preprint":false},{"pmid":"29883404","id":"PMC_29883404","title":"The CD36-PPARγ Pathway in Metabolic Disorders.","date":"2018","source":"International journal of molecular sciences","url":"https://pubmed.ncbi.nlm.nih.gov/29883404","citation_count":142,"is_preprint":false},{"pmid":"21251979","id":"PMC_21251979","title":"Minireview: PPARγ as the target of obesogens.","date":"2011","source":"The Journal of steroid biochemistry and molecular biology","url":"https://pubmed.ncbi.nlm.nih.gov/21251979","citation_count":141,"is_preprint":false},{"pmid":"22334075","id":"PMC_22334075","title":"PPARγ contributes to PKM2 and HK2 expression in fatty liver.","date":"2012","source":"Nature communications","url":"https://pubmed.ncbi.nlm.nih.gov/22334075","citation_count":132,"is_preprint":false},{"pmid":"19906796","id":"PMC_19906796","title":"Selective peroxisome proliferator-activated receptor gamma (PPARgamma) modulation as a strategy for safer therapeutic PPARgamma activation.","date":"2009","source":"The American journal of clinical nutrition","url":"https://pubmed.ncbi.nlm.nih.gov/19906796","citation_count":130,"is_preprint":false},{"pmid":"18926294","id":"PMC_18926294","title":"The many faces of PPARgamma: anti-inflammatory by any means?","date":"2008","source":"Immunobiology","url":"https://pubmed.ncbi.nlm.nih.gov/18926294","citation_count":125,"is_preprint":false},{"pmid":"20863714","id":"PMC_20863714","title":"PPARγ in bone homeostasis.","date":"2010","source":"Trends in endocrinology and metabolism: TEM","url":"https://pubmed.ncbi.nlm.nih.gov/20863714","citation_count":121,"is_preprint":false},{"pmid":"17611413","id":"PMC_17611413","title":"MAPK kinases as nucleo-cytoplasmic shuttles for PPARgamma.","date":"2007","source":"Cell cycle (Georgetown, Tex.)","url":"https://pubmed.ncbi.nlm.nih.gov/17611413","citation_count":120,"is_preprint":false},{"pmid":"26068133","id":"PMC_26068133","title":"Pharmacological repression of PPARγ promotes osteogenesis.","date":"2015","source":"Nature communications","url":"https://pubmed.ncbi.nlm.nih.gov/26068133","citation_count":108,"is_preprint":false},{"pmid":"14555212","id":"PMC_14555212","title":"Peroxisome proliferator-activated receptor gamma (PPARgamma) ligands as bifunctional regulators of cell proliferation.","date":"2003","source":"Biochemical pharmacology","url":"https://pubmed.ncbi.nlm.nih.gov/14555212","citation_count":107,"is_preprint":false},{"pmid":"20810566","id":"PMC_20810566","title":"PPARgamma in placental angiogenesis.","date":"2010","source":"Endocrinology","url":"https://pubmed.ncbi.nlm.nih.gov/20810566","citation_count":94,"is_preprint":false},{"pmid":"20600006","id":"PMC_20600006","title":"Brown vs white adipocytes: the PPARgamma coregulator story.","date":"2010","source":"FEBS letters","url":"https://pubmed.ncbi.nlm.nih.gov/20600006","citation_count":90,"is_preprint":false},{"pmid":"12663371","id":"PMC_12663371","title":"Alanine for proline substitution in the peroxisome proliferator-activated receptor gamma-2 (PPARG2) gene and the risk of incident myocardial infarction.","date":"2003","source":"Arteriosclerosis, thrombosis, and vascular biology","url":"https://pubmed.ncbi.nlm.nih.gov/12663371","citation_count":88,"is_preprint":false},{"pmid":"21605560","id":"PMC_21605560","title":"Epigenetic codes of PPARγ in metabolic disease.","date":"2011","source":"FEBS letters","url":"https://pubmed.ncbi.nlm.nih.gov/21605560","citation_count":85,"is_preprint":false},{"pmid":"27775420","id":"PMC_27775420","title":"The role of PPARgamma in cardiovascular diseases.","date":"2016","source":"Physiological research","url":"https://pubmed.ncbi.nlm.nih.gov/27775420","citation_count":82,"is_preprint":false},{"pmid":"34697317","id":"PMC_34697317","title":"Pparg signaling controls bladder cancer subtype and immune exclusion.","date":"2021","source":"Nature communications","url":"https://pubmed.ncbi.nlm.nih.gov/34697317","citation_count":79,"is_preprint":false},{"pmid":"28243251","id":"PMC_28243251","title":"PPARγ and Its Role in Cardiovascular Diseases.","date":"2017","source":"PPAR research","url":"https://pubmed.ncbi.nlm.nih.gov/28243251","citation_count":77,"is_preprint":false},{"pmid":"27531629","id":"PMC_27531629","title":"PPARγ Regulates Mouse Meibocyte Differentiation and Lipid Synthesis.","date":"2016","source":"The ocular surface","url":"https://pubmed.ncbi.nlm.nih.gov/27531629","citation_count":77,"is_preprint":false},{"pmid":"34697644","id":"PMC_34697644","title":"The Role of PPAR-γ in Allergic Disease.","date":"2021","source":"Current allergy and asthma reports","url":"https://pubmed.ncbi.nlm.nih.gov/34697644","citation_count":75,"is_preprint":false},{"pmid":"19900469","id":"PMC_19900469","title":"Peroxisome proliferator-activated receptor gamma (PPARgamma): Is the genomic activity the only answer?","date":"2009","source":"Steroids","url":"https://pubmed.ncbi.nlm.nih.gov/19900469","citation_count":71,"is_preprint":false},{"pmid":"27422345","id":"PMC_27422345","title":"PPARG Post-translational Modifications Regulate Bone Formation and Bone Resorption.","date":"2016","source":"EBioMedicine","url":"https://pubmed.ncbi.nlm.nih.gov/27422345","citation_count":71,"is_preprint":false},{"pmid":"25734377","id":"PMC_25734377","title":"Peroxisome Proliferator-Activated Receptor γ (PPARγ) and Ligand Choreography: Newcomers Take the Stage.","date":"2015","source":"Journal of medicinal chemistry","url":"https://pubmed.ncbi.nlm.nih.gov/25734377","citation_count":69,"is_preprint":false},{"pmid":"15541649","id":"PMC_15541649","title":"Role of PPARgamma in macrophage biology and atherosclerosis.","date":"2004","source":"Trends in endocrinology and metabolism: TEM","url":"https://pubmed.ncbi.nlm.nih.gov/15541649","citation_count":69,"is_preprint":false},{"pmid":"32218693","id":"PMC_32218693","title":"ACSL1 affects Triglyceride Levels through the PPARγ Pathway.","date":"2020","source":"International journal of medical sciences","url":"https://pubmed.ncbi.nlm.nih.gov/32218693","citation_count":65,"is_preprint":false},{"pmid":"15811195","id":"PMC_15811195","title":"PPARgamma and atherosclerosis.","date":"2005","source":"Current medical research and opinion","url":"https://pubmed.ncbi.nlm.nih.gov/15811195","citation_count":63,"is_preprint":false},{"pmid":"25071153","id":"PMC_25071153","title":"Gcn5 and PCAF regulate PPARγ and Prdm16 expression to facilitate brown adipogenesis.","date":"2014","source":"Molecular and cellular biology","url":"https://pubmed.ncbi.nlm.nih.gov/25071153","citation_count":57,"is_preprint":false},{"pmid":"20204748","id":"PMC_20204748","title":"PPARgamma and the pathobiology of pulmonary arterial hypertension.","date":"2010","source":"Advances in experimental medicine and biology","url":"https://pubmed.ncbi.nlm.nih.gov/20204748","citation_count":55,"is_preprint":false},{"pmid":"21704384","id":"PMC_21704384","title":"PPARγ and human trophoblast differentiation.","date":"2011","source":"Journal of reproductive immunology","url":"https://pubmed.ncbi.nlm.nih.gov/21704384","citation_count":53,"is_preprint":false},{"pmid":"18317437","id":"PMC_18317437","title":"The antifibrogenic potential of PPARgamma ligands in pulmonary fibrosis.","date":"2008","source":"Journal of investigative medicine : the official publication of the American Federation for Clinical Research","url":"https://pubmed.ncbi.nlm.nih.gov/18317437","citation_count":53,"is_preprint":false},{"pmid":"32758586","id":"PMC_32758586","title":"Minutes of PPAR-γ agonism and neuroprotection.","date":"2020","source":"Neurochemistry international","url":"https://pubmed.ncbi.nlm.nih.gov/32758586","citation_count":52,"is_preprint":false},{"pmid":"25316675","id":"PMC_25316675","title":"Thrap3 docks on phosphoserine 273 of PPARγ and controls diabetic gene programming.","date":"2014","source":"Genes & development","url":"https://pubmed.ncbi.nlm.nih.gov/25316675","citation_count":51,"is_preprint":false},{"pmid":"38648706","id":"PMC_38648706","title":"PPARG-mediated autophagy activation alleviates inflammation in rheumatoid arthritis.","date":"2024","source":"Journal of autoimmunity","url":"https://pubmed.ncbi.nlm.nih.gov/38648706","citation_count":50,"is_preprint":false},{"pmid":"18596912","id":"PMC_18596912","title":"PPARgamma and MEK Interactions in Cancer.","date":"2008","source":"PPAR research","url":"https://pubmed.ncbi.nlm.nih.gov/18596912","citation_count":50,"is_preprint":false},{"pmid":"23666678","id":"PMC_23666678","title":"Pro12Ala variant of the PPARG2 gene increases body mass index: An updated meta-analysis encompassing 49,092 subjects.","date":"2013","source":"Obesity (Silver Spring, Md.)","url":"https://pubmed.ncbi.nlm.nih.gov/23666678","citation_count":49,"is_preprint":false},{"pmid":"10936415","id":"PMC_10936415","title":"PPARgamma: observations in the hematopoietic system.","date":"2000","source":"Prostaglandins & other lipid mediators","url":"https://pubmed.ncbi.nlm.nih.gov/10936415","citation_count":49,"is_preprint":false},{"pmid":"34502154","id":"PMC_34502154","title":"The PPARg System in Major Depression: Pathophysiologic and Therapeutic Implications.","date":"2021","source":"International journal of molecular sciences","url":"https://pubmed.ncbi.nlm.nih.gov/34502154","citation_count":47,"is_preprint":false},{"pmid":"29258184","id":"PMC_29258184","title":"Lysophospholipid-Related Diseases and PPARγ Signaling Pathway.","date":"2017","source":"International journal of molecular sciences","url":"https://pubmed.ncbi.nlm.nih.gov/29258184","citation_count":46,"is_preprint":false},{"pmid":"36965374","id":"PMC_36965374","title":"Cannabidiol goes nuclear: The role of PPARγ.","date":"2023","source":"Phytomedicine : international journal of phytotherapy and phytopharmacology","url":"https://pubmed.ncbi.nlm.nih.gov/36965374","citation_count":46,"is_preprint":false},{"pmid":"18619497","id":"PMC_18619497","title":"HDAC1/HDAC3 modulates PPARG2 transcription through the sumoylated CEBPD in hepatic lipogenesis.","date":"2008","source":"Biochimica et biophysica acta","url":"https://pubmed.ncbi.nlm.nih.gov/18619497","citation_count":46,"is_preprint":false},{"pmid":"23627357","id":"PMC_23627357","title":"Lipin1 regulates PPARγ transcriptional activity.","date":"2013","source":"The Biochemical journal","url":"https://pubmed.ncbi.nlm.nih.gov/23627357","citation_count":46,"is_preprint":false},{"pmid":"15711575","id":"PMC_15711575","title":"Atypical transcriptional regulators and cofactors of PPARgamma.","date":"2005","source":"International journal of obesity (2005)","url":"https://pubmed.ncbi.nlm.nih.gov/15711575","citation_count":44,"is_preprint":false},{"pmid":"33086065","id":"PMC_33086065","title":"The Obesity-Susceptibility Gene TMEM18 Promotes Adipogenesis through Activation of PPARG.","date":"2020","source":"Cell reports","url":"https://pubmed.ncbi.nlm.nih.gov/33086065","citation_count":44,"is_preprint":false},{"pmid":"22221092","id":"PMC_22221092","title":"Role of PPARg2 transcription factor in thiazolidinedione-induced insulin sensitization.","date":"2011","source":"The Journal of pharmacy and pharmacology","url":"https://pubmed.ncbi.nlm.nih.gov/22221092","citation_count":43,"is_preprint":false},{"pmid":"33722775","id":"PMC_33722775","title":"PPARG in osteocytes controls sclerostin expression, bone mass, marrow adiposity and mediates TZD-induced bone loss.","date":"2021","source":"Bone","url":"https://pubmed.ncbi.nlm.nih.gov/33722775","citation_count":43,"is_preprint":false},{"pmid":"37701041","id":"PMC_37701041","title":"A glimpse of the connection between PPARγ and macrophage.","date":"2023","source":"Frontiers in pharmacology","url":"https://pubmed.ncbi.nlm.nih.gov/37701041","citation_count":42,"is_preprint":false},{"pmid":"24107916","id":"PMC_24107916","title":"PPARγ against tumors by different signaling pathways.","date":"2013","source":"Onkologie","url":"https://pubmed.ncbi.nlm.nih.gov/24107916","citation_count":41,"is_preprint":false},{"pmid":"36112694","id":"PMC_36112694","title":"C/EBPβ regulates lipid metabolism and Pparg isoform 2 expression in alveolar macrophages.","date":"2022","source":"Science immunology","url":"https://pubmed.ncbi.nlm.nih.gov/36112694","citation_count":38,"is_preprint":false},{"pmid":"19283081","id":"PMC_19283081","title":"PPARgamma in Kidney Physiology and Pathophysiology.","date":"2009","source":"PPAR research","url":"https://pubmed.ncbi.nlm.nih.gov/19283081","citation_count":38,"is_preprint":false},{"pmid":"27579030","id":"PMC_27579030","title":"Commonalities in the Association between PPARG and Vitamin D Related with Obesity and Carcinogenesis.","date":"2016","source":"PPAR research","url":"https://pubmed.ncbi.nlm.nih.gov/27579030","citation_count":37,"is_preprint":false},{"pmid":"20938219","id":"PMC_20938219","title":"The role of PPARγ for the osteoblastic differentiation.","date":"2010","source":"Journal of endocrinological investigation","url":"https://pubmed.ncbi.nlm.nih.gov/20938219","citation_count":36,"is_preprint":false},{"pmid":"28560603","id":"PMC_28560603","title":"Micro-RNA-130a-3p Regulates Gemcitabine Resistance via PPARG in Cholangiocarcinoma.","date":"2017","source":"Annals of surgical oncology","url":"https://pubmed.ncbi.nlm.nih.gov/28560603","citation_count":36,"is_preprint":false},{"pmid":"29654510","id":"PMC_29654510","title":"miR-128-3p regulates 3T3-L1 adipogenesis and lipolysis by targeting Pparg and Sertad2.","date":"2018","source":"Journal of physiology and biochemistry","url":"https://pubmed.ncbi.nlm.nih.gov/29654510","citation_count":36,"is_preprint":false},{"pmid":"16604166","id":"PMC_16604166","title":"Nuclear receptor corepressors and PPARgamma.","date":"2006","source":"Nuclear receptor signaling","url":"https://pubmed.ncbi.nlm.nih.gov/16604166","citation_count":33,"is_preprint":false},{"pmid":"37620972","id":"PMC_37620972","title":"PPARγ activation suppresses chondrocyte ferroptosis through mitophagy in osteoarthritis.","date":"2023","source":"Journal of orthopaedic surgery and research","url":"https://pubmed.ncbi.nlm.nih.gov/37620972","citation_count":33,"is_preprint":false},{"pmid":"22960592","id":"PMC_22960592","title":"PPARγ and stress: implications for aging.","date":"2012","source":"Experimental gerontology","url":"https://pubmed.ncbi.nlm.nih.gov/22960592","citation_count":31,"is_preprint":false},{"pmid":"17659359","id":"PMC_17659359","title":"Peroxisome proliferator-activated receptor gamma (PPARgamma) and colorectal carcinogenesis.","date":"2007","source":"Journal of cancer research and clinical oncology","url":"https://pubmed.ncbi.nlm.nih.gov/17659359","citation_count":31,"is_preprint":false},{"pmid":"37358659","id":"PMC_37358659","title":"Bavachinin Ameliorates Rheumatoid Arthritis Inflammation via PPARG/PI3K/AKT Signaling Pathway.","date":"2023","source":"Inflammation","url":"https://pubmed.ncbi.nlm.nih.gov/37358659","citation_count":31,"is_preprint":false},{"pmid":"26446277","id":"PMC_26446277","title":"Axonal PPARγ promotes neuronal regeneration after injury.","date":"2015","source":"Developmental neurobiology","url":"https://pubmed.ncbi.nlm.nih.gov/26446277","citation_count":31,"is_preprint":false},{"pmid":"32738369","id":"PMC_32738369","title":"Assessing the receptor-mediated activity of PAHs using AhR-, ERα- and PPARγ- CALUX bioassays.","date":"2020","source":"Food and chemical toxicology : an international journal published for the British Industrial Biological Research Association","url":"https://pubmed.ncbi.nlm.nih.gov/32738369","citation_count":30,"is_preprint":false},{"pmid":"35011648","id":"PMC_35011648","title":"PPARγ Regulates Triclosan Induced Placental Dysfunction.","date":"2021","source":"Cells","url":"https://pubmed.ncbi.nlm.nih.gov/35011648","citation_count":29,"is_preprint":false},{"pmid":"29233982","id":"PMC_29233982","title":"CACUL1 reciprocally regulates SIRT1 and LSD1 to repress PPARγ and inhibit adipogenesis.","date":"2017","source":"Cell death & disease","url":"https://pubmed.ncbi.nlm.nih.gov/29233982","citation_count":29,"is_preprint":false},{"pmid":"32886507","id":"PMC_32886507","title":"Photohormones Enable Optical Control of the Peroxisome Proliferator-Activated Receptor γ (PPARγ).","date":"2020","source":"Journal of medicinal chemistry","url":"https://pubmed.ncbi.nlm.nih.gov/32886507","citation_count":29,"is_preprint":false},{"pmid":"37334066","id":"PMC_37334066","title":"PPARG: A Promising Therapeutic Target in Breast Cancer and Regulation by Natural Drugs.","date":"2023","source":"PPAR research","url":"https://pubmed.ncbi.nlm.nih.gov/37334066","citation_count":28,"is_preprint":false},{"pmid":"32239932","id":"PMC_32239932","title":"Insights into PPARγ Phosphorylation and Its Inhibition Mechanism.","date":"2020","source":"Journal of medicinal chemistry","url":"https://pubmed.ncbi.nlm.nih.gov/32239932","citation_count":27,"is_preprint":false},{"pmid":"32446390","id":"PMC_32446390","title":"Promotion of lipogenesis by PPARγ-activated FXR expression in adipocytes.","date":"2020","source":"Biochemical and biophysical research communications","url":"https://pubmed.ncbi.nlm.nih.gov/32446390","citation_count":27,"is_preprint":false},{"pmid":"34445309","id":"PMC_34445309","title":"Analysis of PPARγ Signaling Activity in Psoriasis.","date":"2021","source":"International journal of molecular sciences","url":"https://pubmed.ncbi.nlm.nih.gov/34445309","citation_count":26,"is_preprint":false},{"pmid":"27774097","id":"PMC_27774097","title":"PPARγ in Bacterial Infections: A Friend or Foe?","date":"2016","source":"PPAR research","url":"https://pubmed.ncbi.nlm.nih.gov/27774097","citation_count":25,"is_preprint":false},{"pmid":"31367941","id":"PMC_31367941","title":"Sirt1 inhibits gouty arthritis via activating PPARγ.","date":"2019","source":"Clinical rheumatology","url":"https://pubmed.ncbi.nlm.nih.gov/31367941","citation_count":25,"is_preprint":false},{"pmid":"31297878","id":"PMC_31297878","title":"YAP1 regulates PPARG and RXR alpha expression to affect the proliferation and differentiation of ovine preadipocyte.","date":"2019","source":"Journal of cellular biochemistry","url":"https://pubmed.ncbi.nlm.nih.gov/31297878","citation_count":25,"is_preprint":false},{"pmid":"20676693","id":"PMC_20676693","title":"PPARγ and chronic kidney disease.","date":"2010","source":"Pediatric nephrology (Berlin, Germany)","url":"https://pubmed.ncbi.nlm.nih.gov/20676693","citation_count":24,"is_preprint":false},{"pmid":"25744070","id":"PMC_25744070","title":"PPARγ Maintains Homeostasis through Autophagy Regulation in Dental Pulp.","date":"2015","source":"Journal of dental research","url":"https://pubmed.ncbi.nlm.nih.gov/25744070","citation_count":24,"is_preprint":false},{"pmid":"19850645","id":"PMC_19850645","title":"Rosiglitazone activation of PPARgamma suppresses fractalkine signaling.","date":"2009","source":"Journal of molecular endocrinology","url":"https://pubmed.ncbi.nlm.nih.gov/19850645","citation_count":24,"is_preprint":false},{"pmid":"33663364","id":"PMC_33663364","title":"Glitazones, PPAR-γ and Neuroprotection.","date":"2021","source":"Mini reviews in medicinal chemistry","url":"https://pubmed.ncbi.nlm.nih.gov/33663364","citation_count":23,"is_preprint":false},{"pmid":"35149744","id":"PMC_35149744","title":"LPIN1 promotes triglycerides synthesis and is transcriptionally regulated by PPARG in buffalo mammary epithelial cells.","date":"2022","source":"Scientific reports","url":"https://pubmed.ncbi.nlm.nih.gov/35149744","citation_count":23,"is_preprint":false},{"pmid":"12412636","id":"PMC_12412636","title":"Biology and toxicology of PPARgamma ligands.","date":"2002","source":"Human & experimental toxicology","url":"https://pubmed.ncbi.nlm.nih.gov/12412636","citation_count":22,"is_preprint":false},{"pmid":"31814555","id":"PMC_31814555","title":"PPARγ Agonists in Combination Cancer Therapies.","date":"2020","source":"Current cancer drug targets","url":"https://pubmed.ncbi.nlm.nih.gov/31814555","citation_count":21,"is_preprint":false},{"pmid":"30121577","id":"PMC_30121577","title":"Inhibition of PPARγ, adipogenesis and insulin sensitivity by MAGED1.","date":"2018","source":"The Journal of endocrinology","url":"https://pubmed.ncbi.nlm.nih.gov/30121577","citation_count":20,"is_preprint":false},{"pmid":"18779872","id":"PMC_18779872","title":"CXCR4 in Cancer and Its Regulation by PPARgamma.","date":"2008","source":"PPAR research","url":"https://pubmed.ncbi.nlm.nih.gov/18779872","citation_count":20,"is_preprint":false},{"pmid":"19900503","id":"PMC_19900503","title":"Peroxisome proliferator-activated receptor-gamma (PPARgamma) modulates hypothalamic Trh regulation in vivo.","date":"2009","source":"Molecular and cellular endocrinology","url":"https://pubmed.ncbi.nlm.nih.gov/19900503","citation_count":20,"is_preprint":false},{"pmid":"31789920","id":"PMC_31789920","title":"PPARγ and RhoBTB1 in hypertension.","date":"2020","source":"Current opinion in nephrology and hypertension","url":"https://pubmed.ncbi.nlm.nih.gov/31789920","citation_count":19,"is_preprint":false},{"pmid":"32455814","id":"PMC_32455814","title":"In-Vitro-Generated Hypertrophic-Like Adipocytes Displaying PPARG Isoforms Unbalance Recapitulate Adipocyte Dysfunctions In Vivo.","date":"2020","source":"Cells","url":"https://pubmed.ncbi.nlm.nih.gov/32455814","citation_count":18,"is_preprint":false},{"pmid":"34813964","id":"PMC_34813964","title":"Ups and downs: The PPARγ/p-PPARγ seesaw of follistatin-like 1 and integrin receptor signaling in adipogenesis.","date":"2021","source":"Molecular metabolism","url":"https://pubmed.ncbi.nlm.nih.gov/34813964","citation_count":17,"is_preprint":false},{"pmid":"38468335","id":"PMC_38468335","title":"Nobiletin alleviates atherosclerosis by inhibiting lipid uptake via the PPARG/CD36 pathway.","date":"2024","source":"Lipids in health and disease","url":"https://pubmed.ncbi.nlm.nih.gov/38468335","citation_count":16,"is_preprint":false},{"pmid":"29757190","id":"PMC_29757190","title":"Reversing the curse on PPARγ.","date":"2018","source":"The Journal of clinical investigation","url":"https://pubmed.ncbi.nlm.nih.gov/29757190","citation_count":16,"is_preprint":false}],"cost":{"stage1":{"model":"claude-sonnet-4-6","input_tokens":44700,"output_tokens":6705,"usd":0.117337,"stage1_stop_reason":"end_turn"},"stage2":{"model":"claude-opus-4-8","input_tokens":16113,"output_tokens":4916,"usd":0.101733,"stage2_stop_reason":"end_turn"},"total_usd":0.21907,"stage1_batch_id":"msgbatch_01CNoDbkChHEkgrJnL7BwtGJ","stage2_batch_id":"msgbatch_016Y4x9E9Wg5VQDANj9quSQD","note":"batch pricing = 50% of standard"},"stage1_raw":"```json\n{\n  \"discoveries\": [\n    {\n      \"year\": 1998,\n      \"finding\": \"PPARγ was identified as the major functional receptor for the thiazolidinedione class of insulin-sensitizing drugs; ligand binding by PPARγ leads to cofactor docking in a ligand-dependent fashion, regulating transcriptional activity in adipogenesis and systemic insulin action.\",\n      \"method\": \"Nuclear receptor biochemistry, ligand binding assays, transcriptional reporter assays\",\n      \"journal\": \"Diabetes\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Strong — foundational finding replicated across multiple labs, multiple orthogonal methods including ligand binding and reporter assays\",\n      \"pmids\": [\"9568680\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2002,\n      \"finding\": \"Upon activation, PPARγ heterodimerizes with retinoid X receptor (RXR), recruits specific cofactors, and binds to PPAR-responsive DNA elements to stimulate transcription of target genes involved in glucose and lipid metabolism.\",\n      \"method\": \"Co-immunoprecipitation, reporter assays, chromatin immunoprecipitation\",\n      \"journal\": \"Annual review of nutrition\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Strong — heterodimer formation and DNA binding replicated across multiple independent labs and studies\",\n      \"pmids\": [\"12055342\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2005,\n      \"finding\": \"PPARγ activity is regulated by ERK1/2-mediated phosphorylation of a serine residue, which attenuates its transactivation function; additionally, mitogen-activated MEK1/2 interacts directly with nuclear PPARγ and exports it from the nucleus via MEK's N-terminal nuclear export signal, providing a nucleo-cytoplasmic shuttling mechanism.\",\n      \"method\": \"Co-immunoprecipitation, subcellular fractionation, phosphorylation assays, nuclear export signal mutagenesis\",\n      \"journal\": \"Cell cycle (Georgetown, Tex.)\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — direct interaction and nuclear export demonstrated in single lab with multiple methods\",\n      \"pmids\": [\"17611413\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2008,\n      \"finding\": \"FABP4 triggers the ubiquitination and subsequent proteasomal degradation of PPARγ, thereby downregulating PPARγ protein levels; FABP4-null preadipocytes show increased PPARγ expression and enhanced adipogenesis, and complementation of FABP4 reverses this.\",\n      \"method\": \"Ubiquitination assays, proteasome inhibitor experiments, FABP4 knockout and complementation in preadipocytes and macrophages, Western blotting\",\n      \"journal\": \"Diabetes\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Strong — multiple orthogonal methods (ubiquitination assay, proteasomal inhibition, genetic rescue) in single rigorous study\",\n      \"pmids\": [\"24319114\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2008,\n      \"finding\": \"Klotho is a direct transcriptional target of PPARγ; a noncanonical PPAR-responsive element in the 5'-flanking region of the human klotho gene was identified by ChIP and gel shift assays, and PPARγ agonists increased klotho expression in vivo in mouse kidneys.\",\n      \"method\": \"Chromatin immunoprecipitation (ChIP), electrophoretic mobility shift assay (EMSA), promoter-reporter assays, siRNA knockdown, in vivo adenovirus overexpression\",\n      \"journal\": \"Kidney international\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1–2 / Moderate — ChIP, EMSA, reporter assays, and in vivo validation in single rigorous study\",\n      \"pmids\": [\"18547997\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2008,\n      \"finding\": \"TNF-α inhibits PPARγ activity via activation of serine kinases including IKK, ERK, JNK, and p38; IKK acts as a dominant regulator by both inhibiting PPARγ expression and activating PPARγ corepressors.\",\n      \"method\": \"Kinase activity assays, gene expression analysis, pharmacological kinase inhibition\",\n      \"journal\": \"Biochemical and biophysical research communications\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 3 / Moderate — mechanistic pathway placement from multiple reviewed studies, but this is a review paper summarizing others' and author's experiments\",\n      \"pmids\": [\"18655773\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2008,\n      \"finding\": \"HDAC1 and HDAC3 are recruited to the PPARG2 promoter via sumoylated CEBPD (sumoylation at lysine 120 by SUMO1), forming a repressor complex that inactivates PPARG2 transcription; non-sumoylated CEBPD reverses this repression to activate PPARG2 during hepatic lipogenesis.\",\n      \"method\": \"5'-serial deletion reporter assays, ChIP, co-immunoprecipitation of CEBPD-HDAC1/HDAC3, sumoylation mutant analysis\",\n      \"journal\": \"Biochimica et biophysica acta\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1–2 / Moderate — promoter mapping, ChIP, co-IP, and mutagenesis in a single rigorous study\",\n      \"pmids\": [\"18619497\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2012,\n      \"finding\": \"PPARγ directly binds to the promoters of hexokinase 2 (HK2) and pyruvate kinase M2 (PKM2) to activate their transcription in PTEN-null fatty liver; this activity and liver steatosis/tumorigenesis are under control of Akt2 kinase upstream.\",\n      \"method\": \"Chromatin immunoprecipitation, promoter binding assays, genetic mouse models (PTEN-null, Akt2 knockout)\",\n      \"journal\": \"Nature communications\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1–2 / Moderate — direct promoter binding by ChIP and genetic epistasis in mouse models demonstrated in single rigorous study\",\n      \"pmids\": [\"22334075\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2013,\n      \"finding\": \"Lipin1 directly interacts with PPARγ through a VXXLL motif (residue 885) and a C-terminal region (residues 825–926), releasing co-repressors NCoR1 and SMRT from PPARγ in the absence of ligand, thereby activating PPARγ transcriptional activity and enhancing adipocyte differentiation; a novel transcriptional activation domain (TAD, residues 217–399) unique to lipin1 mediates PPARγ activation but not PPARα.\",\n      \"method\": \"Co-immunoprecipitation, pulldown, reporter assays, domain mutagenesis (VXXLL mutant), chromatin immunoprecipitation\",\n      \"journal\": \"The Biochemical journal\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1–2 / Moderate — reciprocal Co-IP, mutagenesis of binding motif, and reporter assays in single rigorous study\",\n      \"pmids\": [\"23627357\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2014,\n      \"finding\": \"Thrap3 (thyroid hormone receptor-associated protein 3) directly interacts with PPARγ when it is phosphorylated at Ser273 by CDK5; this interaction controls CDK5-mediated diabetic gene programming in adipocytes, including dysregulation of adiponectin and adipsin.\",\n      \"method\": \"Co-immunoprecipitation, mass spectrometry, siRNA knockdown, antisense oligonucleotide treatment in vivo, gene expression profiling\",\n      \"journal\": \"Genes & development\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — co-IP, MS confirmation, in vitro knockdown, and in vivo rescue with multiple orthogonal approaches\",\n      \"pmids\": [\"25316675\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2014,\n      \"finding\": \"Gcn5 and PCAF acetyltransferases act upstream of PPARγ to facilitate adipogenesis by regulating RNA polymerase II elongation of PPARγ transcripts; double knockout of Gcn5/PCAF inhibits PPARγ expression and prevents adipocyte differentiation, which is rescued by ectopic PPARγ expression.\",\n      \"method\": \"Genetic knockout (double KO), ectopic PPARγ expression rescue, RNA pol II ChIP, quantitative gene expression\",\n      \"journal\": \"Molecular and cellular biology\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — genetic epistasis with rescue experiment and ChIP mechanistic data in single study\",\n      \"pmids\": [\"25071153\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2015,\n      \"finding\": \"Structural analysis of PPARγ revealed the mechanism by which the antagonist SR1664 actively antagonizes PPARγ; this enabled development of SR2595 as an inverse agonist that represses PPARγ and promotes osteogenic differentiation of bone marrow-derived mesenchymal stem cells.\",\n      \"method\": \"X-ray crystallography, structural biology, cell differentiation assays with bone marrow-derived MSCs\",\n      \"journal\": \"Nature communications\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 / Moderate — structural (crystal) data plus functional validation in primary cells in single rigorous study\",\n      \"pmids\": [\"26068133\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2015,\n      \"finding\": \"PPARγ protein and mRNA are present within sensory axons; after sciatic nerve injury, PPARγ protein levels increase in axons with increased retrograde transport via association with dynein, and PPARγ accumulates in the nucleus of sensory neuron cell bodies; PPARγ antagonists attenuate axonal regeneration.\",\n      \"method\": \"Immunofluorescence localization, subcellular fractionation, retrograde transport assays, co-immunoprecipitation with dynein, loss-of-function with PPARγ antagonists\",\n      \"journal\": \"Developmental neurobiology\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — direct localization, co-IP with dynein, and functional loss-of-function in same study; single lab\",\n      \"pmids\": [\"26446277\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2016,\n      \"finding\": \"Post-translational modifications of PPARγ at S112 and S273 differentially regulate bone biology: pS112 controls osteoblastic activity and pS273 controls osteoclastic activity; the inverse agonist SR10171 blocks pS273 but not pS112, increasing trabecular/cortical bone and normalizing metabolic parameters in vivo.\",\n      \"method\": \"In vivo mouse models (normoglycemic and hyperglycemic), phospho-specific antibodies, bone histomorphometry, pharmacological intervention\",\n      \"journal\": \"EBioMedicine\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — phospho-specific reagents, in vivo pharmacological rescue; single lab, two phenotypic endpoints\",\n      \"pmids\": [\"27422345\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2016,\n      \"finding\": \"PPARγ directly binds to PPAR-responsive elements (PPRE) in the FXR gene promoter in adipocytes (demonstrated by ChIP), activating FXR expression in a PPARγ agonist-dependent manner; FXR in turn binds FXRE in the SCD gene promoter to promote lipogenesis.\",\n      \"method\": \"Chromatin immunoprecipitation (ChIP), promoter reporter assays, site mutagenesis\",\n      \"journal\": \"Biochemical and biophysical research communications\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 1–2 / Moderate — ChIP and mutagenesis in single study confirming direct promoter binding\",\n      \"pmids\": [\"32446390\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2017,\n      \"finding\": \"CACUL1 directly binds to PPARγ through a CoRNR box 2 motif and represses PPARγ transcriptional activity and adipogenesis; CACUL1 depletion results in increased histone H3K9 acetylation and decreased H3K9 methylation at PPARγ-responsive gene promoters, through reciprocal regulation of SIRT1 and LSD1 recruitment.\",\n      \"method\": \"Co-immunoprecipitation, ChIP for histone marks, RNA-seq, siRNA knockdown, domain mutagenesis\",\n      \"journal\": \"Cell death & disease\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — reciprocal Co-IP with domain mapping, ChIP histone marks, RNA-seq, and functional rescue in a single multi-method study\",\n      \"pmids\": [\"29233982\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2018,\n      \"finding\": \"MAGED1 directly binds to PPARγ and suppresses its stability and transcriptional activity; MAGED1-deficient mice show increased PPARγ protein levels, more adipocyte precursors, and hyperplasia of white adipose tissue, along with improved insulin sensitivity.\",\n      \"method\": \"Co-immunoprecipitation, protein stability assays, MAGED1 knockout mice, gene expression analysis\",\n      \"journal\": \"The Journal of endocrinology\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — co-IP, KO mouse phenotype, and protein stability analysis; single lab\",\n      \"pmids\": [\"30121577\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2020,\n      \"finding\": \"Structural and conformational analysis (X-ray crystallography, NMR, HDX, MD simulations, site-directed mutagenesis) revealed that CDK5 phosphorylates PPARγ at S245 (equivalent to S273 in full-length); ligand binding can allosterically block CDK5 interaction with PPARγ from a distal site, inhibiting phosphorylation via conformational change.\",\n      \"method\": \"X-ray crystallography, NMR, HDX, protein-protein docking, MD simulations, site-directed mutagenesis\",\n      \"journal\": \"Journal of medicinal chemistry\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 / Moderate — multiple structural methods plus mutagenesis in single rigorous mechanistic study\",\n      \"pmids\": [\"32239932\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2020,\n      \"finding\": \"TMEM18 activates PPARG, particularly upregulating PPARG1 promoter activity; TMEM18 knockdown impairs adipocyte formation in zebrafish and human preadipocytes, placing TMEM18 upstream of PPARγ as a regulator of adipogenesis.\",\n      \"method\": \"Promoter reporter assays, siRNA knockdown, zebrafish loss-of-function, human preadipocyte differentiation assays\",\n      \"journal\": \"Cell reports\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — promoter assay plus in vivo zebrafish model and human cell validation; single lab\",\n      \"pmids\": [\"33086065\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2021,\n      \"finding\": \"PPARγ in osteocytes is essential for sclerostin (SOST) production; PPARγ directly binds to PPREs in the 8 kb upstream region of the Sost gene promoter, as shown by ChIP; osteocyte-specific PPARγ deletion (γOTKO) results in increased bone mass, reduced bone marrow adiposity, and protection from TZD-induced bone loss.\",\n      \"method\": \"Osteocyte-specific conditional knockout mice (Dmp1Cre), ChIP for PPARG binding at Sost promoter PPREs, site mutagenesis, gene expression correlation analysis\",\n      \"journal\": \"Bone\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1–2 / Moderate — conditional KO with in vivo phenotype, ChIP with PPRE mutagenesis, and in vivo pharmacological rescue in single rigorous study\",\n      \"pmids\": [\"33722775\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2009,\n      \"finding\": \"PPARγ activation by rosiglitazone in macrophages represses fractalkine receptor (FR) gene transcription and prevents FR plasma membrane translocation; in endothelial cells, rosiglitazone impedes nuclear export of fractalkine (FKN), revealing a novel anti-inflammatory mechanism of PPARγ.\",\n      \"method\": \"Gene expression analysis, subcellular fractionation/immunofluorescence for receptor localization, nuclear export assays\",\n      \"journal\": \"Journal of molecular endocrinology\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — direct localization experiments plus transcriptional repression in two cell types; single lab\",\n      \"pmids\": [\"19850645\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2009,\n      \"finding\": \"PPARγ modulates hypothalamic TRH regulation in vivo; PPARγ agonist injection modified TRH-luc transcription in newborn mouse hypothalamus; PPARγ overexpression abrogated T3-dependent Trh repression, while RXRα overexpression rescued this effect, indicating competition for RXR as a mechanism of crosstalk between PPARγ and TRβ.\",\n      \"method\": \"In vivo intracerebral injection, reporter gene (TRH-luc) assay, shRNA knockdown, adenoviral overexpression, qPCR\",\n      \"journal\": \"Molecular and cellular endocrinology\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — in vivo reporter assay, genetic knockdown, and overexpression rescue with RXR in single study\",\n      \"pmids\": [\"19900503\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2022,\n      \"finding\": \"C/EBPβ (LAP* and LAP isoforms) together with CSF2 signaling selectively induces expression of Pparg isoform 2 but not isoform 1 in alveolar macrophages; C/EBPβ-deficient AMs show severe defects in proliferation, phagocytosis, and lipid metabolism causing a PAP-like syndrome.\",\n      \"method\": \"Transcriptome analysis, chromatin accessibility (ATAC-seq), conditional knockout mice, functional assays (proliferation, phagocytosis, lipid metabolism)\",\n      \"journal\": \"Science immunology\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — conditional KO with transcriptomic and functional readouts; single lab study\",\n      \"pmids\": [\"36112694\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2016,\n      \"finding\": \"PPARγ activation with rosiglitazone stimulates lipid synthesis in mouse meibocytes, associated with SUMO1 sumoylation of the 72 kDa PPARγ isoform and its cytoplasmic accumulation; loss of cytoplasmic PPARγ was observed in aged atrophic meibomian glands.\",\n      \"method\": \"Subcellular fractionation, immunoblotting (anti-SUMO1), CARS/Raman microspectroscopy, LipidTox staining, mRNA quantification\",\n      \"journal\": \"The ocular surface\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 3 / Moderate — sumoylation demonstrated by antibody-based methods and correlated with cytoplasmic localization and lipid synthesis; single lab\",\n      \"pmids\": [\"27531629\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2021,\n      \"finding\": \"Pparg activation in basal bladder urothelial progenitors induces superficial cell formation and cell cycle exit, preventing tumor formation; however, in injury-activated progenitors, Pparg activation results in luminal tumor formation that is immune-deserted, linked to downregulation of NF-κB as a Pparg target.\",\n      \"method\": \"Transgenic mouse model (VP16;Pparg activated form), in situ histology, immunofluorescence, gene expression analysis\",\n      \"journal\": \"Nature communications\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — in vivo genetic model with phenotypic and molecular readouts; single lab\",\n      \"pmids\": [\"34697317\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2010,\n      \"finding\": \"PPARγ activation promotes osteoclastogenesis through a transcriptional network comprising PPARγ, PGC-1β, and ERRα, which promotes both osteoclast differentiation and mitochondrial activation; PPARγ also suppresses osteoblastogenesis, creating dual opposing effects on bone homeostasis.\",\n      \"method\": \"Genetic mouse models, cell differentiation assays, gene expression analysis, reporter assays\",\n      \"journal\": \"Trends in endocrinology and metabolism: TEM\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — mechanistic review summarizing in vivo genetic findings; pathway placement supported by multiple studies cited\",\n      \"pmids\": [\"20863714\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2009,\n      \"finding\": \"PPARγ plays a pivotal role in controlling placental vascular proliferation; PPARγ-null embryos show unsettled balance of pro- (proliferin/PLF) and anti-angiogenic factors (proliferin-related protein/PRP), and PPARγ agonist rosiglitazone treatment disrupts placental vasculature and decreases proangiogenic gene expression.\",\n      \"method\": \"Conditional knockout mice (Sox2Cre/PPARγL2/L2), in vivo rosiglitazone treatment, gene expression analysis\",\n      \"journal\": \"Endocrinology\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — genetic KO plus pharmacological intervention with defined molecular readouts; single lab\",\n      \"pmids\": [\"20810566\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2022,\n      \"finding\": \"PPARγ directly regulates buffalo LPIN1 transcription by binding to two PPAR response elements (PPRE1 and PPRE2) identified in the core LPIN1 promoter region (−666 to +42 bp); site mutagenesis confirmed both PPREs are required for PPARγ-dependent LPIN1 activation and triglyceride synthesis in mammary epithelial cells.\",\n      \"method\": \"Chromatin immunoprecipitation, promoter reporter assays, site-directed mutagenesis of PPREs, overexpression/knockdown\",\n      \"journal\": \"Scientific reports\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 1–2 / Moderate — ChIP plus PPRE mutagenesis in functional assay; single lab in non-human model (buffalo)\",\n      \"pmids\": [\"35149744\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2024,\n      \"finding\": \"PPARG activation promotes autophagy to accelerate ROS clearance, thereby inhibiting ROS-mediated macrophage polarization and NLRP3 inflammasome activation in rheumatoid arthritis; CBD acts as a PPARγ agonist mediating this pathway.\",\n      \"method\": \"In vitro RAW264.7 cell assays, CIA rat model, autophagy flux assays, ROS measurement, NLRP3 inflammasome assays\",\n      \"journal\": \"Journal of autoimmunity\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — in vitro and in vivo models with mechanistic autophagy/ROS/NLRP3 pathway readouts; single lab\",\n      \"pmids\": [\"38648706\"],\n      \"is_preprint\": false\n    }\n  ],\n  \"current_model\": \"PPARγ (PPARG) is a ligand-activated nuclear receptor that heterodimerizes with RXR to bind PPAR-responsive elements and activate transcription of target genes governing adipogenesis, lipid/glucose metabolism, and inflammation; its activity is regulated by post-translational modifications (phosphorylation at S112 by ERK and S273 by CDK5, sumoylation, ubiquitination leading to proteasomal degradation), direct interactions with co-repressors (NCoR1, SMRT, HDAC1/3 via sumoylated CEBPD) and co-activators (lipin1, Thrap3), nucleo-cytoplasmic shuttling mediated by MEK1/2, and upstream regulation by factors including FABP4 (promoting PPARγ degradation), CACUL1 (recruiting SIRT1/LSD1), and MAGED1 (suppressing stability and activity), collectively determining cell-type-specific transcriptional programs in adipocytes, osteocytes, macrophages, neurons, and other tissues.\"\n}\n```","stage2_raw":"{\n  \"mechanistic_narrative\": \"PPARγ is a ligand-activated nuclear receptor that, upon binding thiazolidinedione drugs and other ligands, drives cofactor docking and transcriptional programs governing adipogenesis, lipid and glucose metabolism, and inflammation [#0]. Activated PPARγ heterodimerizes with RXR, recruits cofactors, and binds PPAR-responsive elements (PPREs) to stimulate metabolic target genes [#1]; direct, ChIP-validated targets include klotho [#4], the glycolytic enzymes HK2 and PKM2 in fatty liver [#7], FXR in adipocytes [#14], LPIN1 in mammary epithelium [#27], and the osteocyte gene Sost/sclerostin [#19]. Its output is tuned by post-translational modification and cofactor exchange: ERK1/2 phosphorylates a serine that attenuates transactivation while MEK1/2 binds nuclear PPARγ and exports it to the cytoplasm [#2], and CDK5 phosphorylates S273/S245, a modification that recruits Thrap3 to reprogram diabetic gene expression and that ligand binding can allosterically block from a distal site [#9, #17]. PPARγ stability is controlled by ubiquitin-proteasome turnover triggered by FABP4 [#3] and by direct binding of MAGED1, which suppresses receptor stability and activity [#16]. Cofactor balance determines activation versus repression: lipin1 displaces the NCoR1/SMRT co-repressors to activate the receptor [#8], whereas CACUL1 binds a CoRNR-box motif and represses PPARγ by reciprocally tuning SIRT1/LSD1 recruitment and histone H3K9 modifications [#15]; PPARG2 expression itself is gated by an HDAC1/HDAC3 co-repressor complex tethered via sumoylated CEBPD [#6]. Beyond adipocytes, PPARγ exerts cell-type-specific roles in bone, where pS112 and pS273 differentially control osteoblastic and osteoclastic activity [#13, #19], in macrophages and inflammation [#20, #28], and in sensory neurons, where it undergoes dynein-dependent retrograde axonal transport supporting regeneration [#12]. Structural studies of inverse agonists (SR2595, SR10171) demonstrate that pharmacological repression of PPARγ promotes osteogenic differentiation and increases bone mass [#11, #13].\"\n,\n  \"teleology\": [\n    {\n      \"year\": 1998,\n      \"claim\": \"Established PPARγ as the molecular target of insulin-sensitizing thiazolidinediones, linking a nuclear receptor to systemic glucose control via ligand-dependent transcription.\",\n      \"evidence\": \"nuclear receptor ligand-binding and transcriptional reporter assays\",\n      \"pmids\": [\"9568680\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Endogenous physiological ligands not defined\", \"Tissue-specific target gene sets not yet mapped\"]\n    },\n    {\n      \"year\": 2002,\n      \"claim\": \"Defined the core transcriptional mechanism: ligand-activated PPARγ heterodimerizes with RXR and binds PPREs to activate metabolic genes.\",\n      \"evidence\": \"Co-IP, reporter assays, and ChIP\",\n      \"pmids\": [\"12055342\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Genome-wide target catalog incomplete\", \"Cofactor specificity by cell type unresolved\"]\n    },\n    {\n      \"year\": 2005,\n      \"claim\": \"Showed that PPARγ activity is dynamically restrained by MAPK signaling through ERK-mediated serine phosphorylation and MEK1/2-driven nuclear export, a non-genomic spatial control mechanism.\",\n      \"evidence\": \"Co-IP, subcellular fractionation, phosphorylation assays, and NES mutagenesis\",\n      \"pmids\": [\"17611413\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Single-lab findings\", \"Quantitative contribution of export to physiological output unknown\"]\n    },\n    {\n      \"year\": 2008,\n      \"claim\": \"Identified multiple layers of negative regulation — FABP4-driven ubiquitination/degradation, TNF-α/IKK-mediated suppression, and sumoylated-CEBPD-tethered HDAC repressor complexes at the PPARG2 promoter — clarifying how receptor abundance and PPARG2 transcription are dampened.\",\n      \"evidence\": \"ubiquitination/proteasome assays, FABP4 knockout/complementation, kinase inhibition, promoter mapping, ChIP, and sumoylation-mutant analysis\",\n      \"pmids\": [\"24319114\", \"18655773\", \"18619497\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"E3 ligase mediating FABP4-triggered ubiquitination not identified\", \"Interplay among these repressive inputs not integrated\"]\n    },\n    {\n      \"year\": 2008,\n      \"claim\": \"Extended the direct target repertoire by demonstrating PPARγ binds a noncanonical PPRE in the klotho promoter, connecting the receptor to renal klotho expression in vivo.\",\n      \"evidence\": \"ChIP, EMSA, reporter assays, and in vivo agonist treatment\",\n      \"pmids\": [\"18547997\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Physiological consequence of klotho induction not fully defined\"]\n    },\n    {\n      \"year\": 2012,\n      \"claim\": \"Placed PPARγ within an Akt2-controlled circuit driving glycolytic gene expression (HK2, PKM2) in PTEN-null fatty liver, linking the receptor to steatosis and tumorigenesis.\",\n      \"evidence\": \"ChIP and genetic mouse epistasis (PTEN-null, Akt2 knockout)\",\n      \"pmids\": [\"22334075\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Generality beyond PTEN-null context unknown\"]\n    },\n    {\n      \"year\": 2013,\n      \"claim\": \"Resolved a ligand-independent activation route: lipin1 binds via a VXXLL motif and a unique TAD to displace NCoR1/SMRT co-repressors, activating PPARγ and adipogenesis.\",\n      \"evidence\": \"reciprocal Co-IP, pulldown, domain mutagenesis, reporter assays, and ChIP\",\n      \"pmids\": [\"23627357\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"In vivo relevance of lipin1-driven activation not quantified\"]\n    },\n    {\n      \"year\": 2014,\n      \"claim\": \"Defined how the diabetes-associated CDK5-S273 phosphorylation is decoded — Thrap3 binds the phosphorylated receptor to reprogram adipocyte gene expression — and showed Gcn5/PCAF acetyltransferases act upstream by enabling Pol II elongation of Pparg transcripts.\",\n      \"evidence\": \"Co-IP/MS, knockdown, in vivo antisense rescue, double-knockout with ectopic-PPARγ rescue, and Pol II ChIP\",\n      \"pmids\": [\"25316675\", \"25071153\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Full Thrap3-dependent gene program not delineated\", \"Acetyltransferase mechanism on other loci unclear\"]\n    },\n    {\n      \"year\": 2015,\n      \"claim\": \"Used structure-guided design to develop SR1664-derived inverse agonists (SR2595) that repress PPARγ and redirect bone-marrow MSCs toward osteogenesis, establishing antagonism as a route to alter cell fate.\",\n      \"evidence\": \"X-ray crystallography and MSC differentiation assays\",\n      \"pmids\": [\"26068133\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Long-term in vivo efficacy and selectivity not established\"]\n    },\n    {\n      \"year\": 2016,\n      \"claim\": \"Demonstrated that distinct phosphosites partition PPARγ's skeletal effects (pS112 → osteoblastic, pS273 → osteoclastic), with SR10171 selectively blocking pS273 to increase bone and normalize metabolism, and described isoform-specific sumoylation/cytoplasmic localization in lipid-synthesizing meibocytes.\",\n      \"evidence\": \"in vivo mouse models with phospho-specific antibodies, bone histomorphometry, and subcellular fractionation with anti-SUMO1 immunoblotting\",\n      \"pmids\": [\"27422345\", \"27531629\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Single-lab phenotypes\", \"Mechanistic link between sumoylation and cytoplasmic retention not fully resolved\"]\n    },\n    {\n      \"year\": 2017,\n      \"claim\": \"Identified CACUL1 as a CoRNR-box co-repressor that represses PPARγ by reciprocally tuning SIRT1/LSD1 recruitment and H3K9 acetylation/methylation, refining the epigenetic logic of receptor output.\",\n      \"evidence\": \"Co-IP with domain mapping, histone-mark ChIP, RNA-seq, and knockdown\",\n      \"pmids\": [\"29233982\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Physiological adipose role of CACUL1 not tested in vivo\"]\n    },\n    {\n      \"year\": 2018,\n      \"claim\": \"Showed MAGED1 directly binds and destabilizes PPARγ, with MAGED1 loss increasing receptor levels, adipocyte precursors, and insulin sensitivity, adding a stability-control input to the network.\",\n      \"evidence\": \"Co-IP, protein stability assays, and MAGED1 knockout mice\",\n      \"pmids\": [\"30121577\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Single-lab study\", \"Degradation machinery engaged by MAGED1 unspecified\"]\n    },\n    {\n      \"year\": 2020,\n      \"claim\": \"Provided high-resolution mechanism for ligand-mediated suppression of pathogenic phosphorylation: CDK5 modifies S245/S273, and ligand binding allosterically blocks CDK5 docking from a distal site, and identified TMEM18 as an upstream activator of the PPARG1 promoter required for adipogenesis.\",\n      \"evidence\": \"X-ray/NMR/HDX/MD with mutagenesis; promoter reporter assays with zebrafish and human preadipocyte loss-of-function\",\n      \"pmids\": [\"32239932\", \"33086065\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"How TMEM18 reaches the promoter mechanistically unknown\", \"Structural model of full-length receptor-CDK5 complex incomplete\"]\n    },\n    {\n      \"year\": 2021,\n      \"claim\": \"Established cell-type-specific in vivo functions: osteocyte PPARγ directly drives Sost/sclerostin via promoter PPREs, and bladder urothelial PPARγ governs differentiation versus immune-deserted tumor formation depending on progenitor state.\",\n      \"evidence\": \"conditional/transgenic mouse models, ChIP with PPRE mutagenesis, and histology/expression analysis\",\n      \"pmids\": [\"33722775\", \"34697317\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Context-dependence of tumor-promoting versus protective output not mechanistically reconciled\"]\n    },\n    {\n      \"year\": 2024,\n      \"claim\": \"Linked PPARγ activation to anti-inflammatory autophagy: agonism accelerates ROS clearance to limit macrophage polarization and NLRP3 inflammasome activation in arthritis models.\",\n      \"evidence\": \"RAW264.7 assays, CIA rat model, autophagy flux, ROS and NLRP3 readouts\",\n      \"pmids\": [\"38648706\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Direct transcriptional targets mediating autophagy not identified\", \"Single-lab study\"]\n    },\n    {\n      \"year\": null,\n      \"claim\": \"How the competing stability inputs (FABP4, MAGED1), cofactor exchanges (lipin1, CACUL1, Thrap3), and phosphorylation states are integrated to specify distinct tissue programs — and which endogenous ligands drive each — remains unresolved.\",\n      \"evidence\": \"\",\n      \"pmids\": [],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"No unified model linking PTM state to cofactor selection per cell type\", \"Endogenous ligand identity per context undefined\", \"E3 ligases controlling degradation not fully identified\"]\n    }\n  ],\n  \"mechanism_profile\": {\n    \"molecular_activity\": [\n      {\"term_id\": \"GO:0140110\", \"supporting_discovery_ids\": [0, 1, 4, 7, 14, 19, 27]},\n      {\"term_id\": \"GO:0003677\", \"supporting_discovery_ids\": [1, 4, 7, 14, 19, 27]},\n      {\"term_id\": \"GO:0008289\", \"supporting_discovery_ids\": [0]}\n    ],\n    \"localization\": [\n      {\"term_id\": \"GO:0005634\", \"supporting_discovery_ids\": [2, 12]},\n      {\"term_id\": \"GO:0005829\", \"supporting_discovery_ids\": [2, 23]}\n    ],\n    \"pathway\": [\n      {\"term_id\": \"R-HSA-74160\", \"supporting_discovery_ids\": [1, 4, 7, 14, 19]},\n      {\"term_id\": \"R-HSA-1430728\", \"supporting_discovery_ids\": [0, 7, 27]},\n      {\"term_id\": \"R-HSA-1266738\", \"supporting_discovery_ids\": [11, 18, 26]},\n      {\"term_id\": \"R-HSA-168256\", \"supporting_discovery_ids\": [20, 22, 28]}\n    ],\n    \"complexes\": [\n      \"PPARγ-RXR heterodimer\"\n    ],\n    \"partners\": [\n      \"RXR\",\n      \"MEK1/2\",\n      \"FABP4\",\n      \"Lipin1\",\n      \"Thrap3\",\n      \"CACUL1\",\n      \"MAGED1\",\n      \"CDK5\"\n    ],\n    \"other_free_text\": []\n  }\n}","audit_flag":null,"evaluation":{"pairwise":"win","faith_supported":7,"faith_total":7,"faith_pct":100.0}}